Lyra Therapeutics (LYRA) AI Stock Analysis

• Market Cap: $1.79M
• Dividend Yield: N/A
• Average Volume (3M): 52.37K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.84
• Revenue Growth: -59.21%
• EPS Growth: 68.97%
• Country: US
• Employees: 30
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -3.38
• Shares Outstanding: 1,774,882
• 10 Day Avg. Volume: 21,342
• 30 Day Avg. Volume: 52,369
• PEG Ratio: -0.53
• Price to Book (P/B): 57.96
• Price to Sales (P/S): 438.05
• P/FCF Ratio: -9.29
• Enterprise Value/Market Cap: 6.20
• Enterprise Value/Revenue: 18.53
• Enterprise Value/Gross Profit: 37.06
• Enterprise Value/Ebitda: -0.36
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): -0.99
• Revenue Forecast (FY): $2.70M

• Rating: 41 Neutral
• Price Target: $1.50 ▼(-24.24% Downside)
• Action: Upgraded Date: 01/29/26
• Date: Action: Upgraded 01/29/26

The score is driven primarily by weak financial performance (minimal revenue, large losses, heavy cash burn, and negative equity) and bearish technicals (price well below key moving averages with negative MACD). A highly negative corporate event (program halt, near-total workforce reduction, leadership changes, and strategic-alternatives process) adds material risk, while valuation metrics offer limited support due to ongoing losses and no dividend.

Positive Factors

Platform technology (XTreo)

A proprietary local extended‑release delivery platform drives durable differentiation in ENT indications by improving local exposure and reducing systemic side effects. This structural advantage supports potential higher efficacy, repeatable product launches, and licensing or partnership value beyond any single asset.

Positive Phase 3 validation

Phase 3 positive data materially de-risks clinical proof‑of‑concept for the lead therapy, strengthening the program's scientific value. That durable validation increases attractiveness to acquirers or partners and raises the likelihood of regulatory paths or monetization even if the company can't self‑fund commercialization.

Near-term cash runway

A cash runway into Q3 2026 provides a multi‑quarter buffer to pursue strategic alternatives, negotiate transactions, or seek partners without immediate insolvency risk. While limited, this runway preserves optionality and enables a more orderly value‑maximizing process over the next 2–6 months.

Negative Factors

Halt of lead program

Suspending development of the lead asset removes the company's primary growth engine and eliminates the internal path to commercialization. This structural step reduces pipeline momentum, erodes R&D capability, and shifts future value realization toward external transactions rather than organic product launches.

Leadership upheaval and strategic uncertainty

Senior management terminations and transition to consulting roles create execution and governance risk, potentially weakening stakeholder confidence. Combined with an active strategic‑alternatives process, the change raises uncertainty around deal execution, continuity of strategy, and the company's ability to negotiate favorable outcomes.

Weak financial profile and cash burn

Very low revenue, persistent large operating losses, negative equity and meaningful debt create structural financing vulnerability. Ongoing cash burn materially increases reliance on external capital or a transaction, restricting strategic options and impairing the firm's ability to fund new development or commercialization internally.

Lyra Therapeutics Business Overview & Revenue Model

Company Description

Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of anti-inflammatory therapies for the treatment of patients with chronic rhinosinusitis. Its technology is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix which is in Phase III clinical trial for the treatment of chronic rhinosinusitis (CRS); and LYR-220 for CRS patients who have failed previous medical management and continue to require treatment to manage CRS symptoms. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.

How the Company Makes Money

Lyra Therapeutics generates revenue primarily through partnerships and collaborations with larger pharmaceutical companies, which may involve licensing deals that provide upfront payments, milestone payments based on development progress, and royalties on future product sales. Additionally, the company may seek funding through grants, public offerings, or private placements to support its research and development activities. As the company progresses its clinical trials and approaches potential commercialization of its products, it may also establish collaborations that enhance its revenue potential.

Lyra Therapeutics Financial Statement Overview

Summary

Financials are very weak: minimal and declining TTM revenue (~$0.6M, ~-22%), large ongoing losses (TTM EBIT about -$34.9M; net loss about -$32.9M), and heavy cash burn (TTM operating cash flow and FCF about -$34.1M). Balance-sheet stress is significant with negative stockholders’ equity (~-$4.3M) alongside meaningful debt (~$31.4M), increasing financing/going-concern risk.

Income Statement

TTM (Trailing-Twelve-Months) revenue is very small ($0.6M) and down ~22% versus the prior period, highlighting weak commercial scale. While gross margin is positive in TTM (~74%), the company remains deeply unprofitable with large operating losses (TTM EBIT about -$34.9M) and a sizable net loss (TTM about -$32.9M), indicating a cost base that materially outweighs current revenue. Losses have persisted across the annual periods shown, with no clear path to earnings stabilization yet.

Balance Sheet

The balance sheet weakened materially: TTM stockholders’ equity is negative (about -$4.3M), which reduces financial flexibility and raises refinancing/going-concern risk. Debt is meaningful (~$31.4M TTM), and leverage metrics deteriorate sharply when equity turns negative. Total assets are ~$43.7M TTM, but the combination of negative equity and ongoing losses makes the capital structure the key constraint despite historically stronger equity levels in earlier years.

Cash Flow

Cash burn remains heavy: TTM operating cash flow is about -$34.1M and free cash flow about -$34.1M, and free cash flow declined further (growth ~-20.7%). Cash outflows are broadly in line with reported net losses, showing losses are translating into real cash usage rather than being mostly non-cash. The magnitude and persistence of negative cash flow imply continued reliance on external financing.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	600.00K	1.53M	1.56M	1.36M	285.00K	0.00
Gross Profit	300.00K	1.53M	1.56M	1.36M	-29.41M	-12.52M
EBITDA	-30.56M	-60.26M	-65.25M	-53.92M	-42.61M	-22.11M
Net Income	-32.95M	-93.44M	-62.68M	-55.28M	-43.51M	-22.13M
Balance Sheet
Total Assets	43.71M	66.35M	142.60M	109.97M	54.87M	80.83M
Cash, Cash Equivalents and Short-Term Investments	22.05M	40.58M	102.75M	97.89M	45.75M	74.59M
Total Debt	31.38M	34.38M	26.88M	4.18M	1.45M	2.44M
Total Liabilities	48.04M	54.75M	53.18M	29.21M	20.55M	6.34M
Stockholders Equity	-4.33M	11.59M	89.42M	80.75M	34.32M	74.49M
Cash Flow
Free Cash Flow	-34.11M	-72.35M	-64.35M	-43.55M	-29.20M	-22.92M
Operating Cash Flow	-34.15M	-70.01M	-63.30M	-43.38M	-25.82M	-21.14M
Investing Cash Flow	28.13M	80.31M	-12.58M	-65.01M	-3.38M	-1.77M
Financing Cash Flow	4.27M	8.53M	65.69M	96.26M	359.00K	87.70M

Lyra Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.98
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Positive
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LYRA, the sentiment is Negative. The current price of 1.98 is above the 20-day moving average (MA) of 1.52, below the 50-day MA of 2.34, and below the 200-day MA of 6.16, indicating a bearish trend. The MACD of -0.31 indicates Negative momentum. The RSI at 26.69 is Positive, neither overbought nor oversold. The STOCH value of 20.99 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for LYRA.

Lyra Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
RNAZ	49 Neutral	$8.81M	-0.04	-1763.01%	―	―	96.75%
BOLT	48 Neutral	$8.68M	-0.20	-81.97%	―	-46.88%	34.83%
SLXN	46 Neutral	$5.75M	-0.07	-771.23%	―	―	91.47%
MBIO	45 Neutral	$7.37M	-0.80	-418.83%	―	―	98.58%
LYRA	41 Neutral	$1.79M	-0.04	-404.48%	―	-59.21%	68.97%
XTLB	39 Underperform	$6.64M	-6.81	―	―	―	65.45%

Lyra Therapeutics Corporate Events

Lyra Therapeutics Halts LYR-210, Cuts Workforce, Explores Options

On January 9, 2026, Lyra Therapeutics’ board approved a plan to suspend further development of its lead chronic rhinosinusitis candidate LYR-210 and to implement a sweeping cost-reduction program, including a workforce reduction affecting nearly all remaining employees as of January 12, 2026, as part of an effort to preserve capital while exploring strategic alternatives. As part of this plan, the employment of CEO and chair Dr. Maria Palasis and CFO and treasurer Jason Cavalier was terminated on January 9, 2026, after which both entered consulting agreements effective January 12, 2026, under which they will continue serving as the company’s principal executive and financial officers, respectively, and may receive enhanced equity vesting and transaction-based bonuses in the event of a change in control exceeding a defined purchase price threshold. The board’s decision to cease product development operations comes despite positive Phase 3 ENLIGHTEN 2 data for LYR-210 reported in June 2025 and a previously established clinical path toward a potential new drug application, underscoring a strategic pivot toward maximizing remaining value for shareholders; the company reported approximately $22.1 million in cash, cash equivalents and short-term investments as of September 30, 2025, and now expects its cash runway to extend into the third quarter of 2026 while it works with SSG Capital Advisors to evaluate potential transactions.

The most recent analyst rating on (LYRA) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Lyra Therapeutics stock, see the LYRA Stock Forecast page.